|
1
|
John CR: Mechanisms of apoptosis. Am J
Pathol. 157:1415–1430. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Homan SG, Steward BR and Armer JM: Public
health and cooperative group partnership: A colorectal cancer
intervention. Semin Oncol Nurs. 30:61–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lv Q, Xing SY and Zhao ZH: Research status
and prospect of colon cancer. Zhong Guo Shi Yan Zhen Duan Xue.
13:1134–1137. 2009.
|
|
5
|
Zheng S and Cai S: Colorectal cancer
epidemiology and prevention study in China. Chinese-German J Clin
Oncol. 2:72–75. 2003. View Article : Google Scholar
|
|
6
|
Tsukuda K, Tanino M, Soga H, Shimizu N and
Shimizu K: A novel activating mutation of the K-ras gene in human
primary colon adenocarcinoma. Biochem Biophys Res Commun.
278:653–658. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tang N and Wang YY: Research progress of
colon cancer related genes. Yi Xue Zong Shu. 18:207–209. 2012.(In
Chinese).
|
|
8
|
Tang WZ, Gao F and Li W: APC mutation in
sporadic colorectal cancer in China. Zhonghua Shi Yan Wai Ke Za
Zhi. 22:1357–1359. 2005.(In Chinese).
|
|
9
|
Wu L, Qian YB and Zhu LX: Promoter
methylation and mRNA expression of APC gene in hepatocellular
carcinoma. Zhonghua Gan Dan Wai Ke Za Zhi. 15:378–381. 2007.(In
Chinese).
|
|
10
|
Cory S and Adams JM: The Bcl 2 family:
Regulators of the cellular life-or-death switch. Nat Rev Cancer.
2:647–656. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhu YS, Lu TY, Wang R, Huang M, Ma Q, Zhao
L, Gao P, Lei X, Ni B, Lin J, et al: Functional conversion of Bcl-2
into a pro-apoptotic molecule to regulate mitochondrial cytochrome
c. Sheng Ming Ke Xue. 23:1076–1080. 2011.(In Chinese).
|
|
12
|
Hockenbery D, Nuñez G, Milliman C,
Schreiber RD and Korsmeyer SJ: Bcl-2 is a inner mitochorndrial
membrane protein that blocks programmed cell death. Nature.
348:334–336. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jia XD and Han C: Biomarkers in the
studies on chemoprevention of colorectal cancer. Wei Sheng Yan Jiu.
29:109–111. 2000.(In Chinese). PubMed/NCBI
|
|
14
|
Gong XZ and Liu W: The role of bcl-2 and
bax gene in colon cancer. Qi Lu Yi Xue Za Zhi. 17:367–370. 2002.(In
Chinese).
|
|
15
|
Chen NL, Chen H, Bai L, Zhang C and Zhao
WH: Expression of cytochrome c in colorectal cancer tissue
and the ultramicro-structural change of mitochondria. Shiyong Yixue
Zazhi. 24:4037–4039. 2008.(In Chinese).
|
|
16
|
Zhang J, Xu B, Cai WS and Li SH: The
effect of Coixenolide extract on the histopathological changes
induce by azoxymethane in rat colon cancer model. Zhongguo Yi Liao
Qian Yan. 6:20–21. 2011.(In Chinese).
|
|
17
|
Rogers AE, Zeisel S and Groopman J: Diet
and carcinogenesis. Carcinogenesis. 14:2205–2217. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Peh YC: Recent advances in colorectal
cancer genetics and diagnostics. Crit Rev Oncol Hematol. 69:45–55.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu RP and Xu GF: Effects of resistant
starch on colonic preneoplastic aberrant crypt foci in rats. Food
Chem Toxicol. 46:2672–2679. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Coleman LJ, Landström EK, Royle PJ, Bird
AR and McIntosh GH: A diet containing alpha-cellulose and fish oil
reduces aberrant crypt foci formation and modulates other possible
markers for colon cancer risk in azoxymethane-treated rats. J Nutr.
132:2312–2318. 2002.PubMed/NCBI
|
|
21
|
Brouns F, Kettlitz B and Arrigoni E:
Resistant starch and ‘the butyrate revolution’. Trends Food Sci
Tech. 13:251–261. 2002. View Article : Google Scholar
|
|
22
|
Englyst HM, Kingman SM and Cummings JH:
Classification and measurement of nutritionally important starch
fractions. Eur J Clin Nutr. 46:(Suppl 2). S33–S50. 1992.PubMed/NCBI
|
|
23
|
Zhou Y, Meng S, Chen D, Zhu X and Yuan H:
Structure characterization and hypoglycemic effects of dual
modified resistant starch from indica rice starch. Carbohyd Polym.
103:81–86. 2014. View Article : Google Scholar
|
|
24
|
Institute of Laboratory Animal Resources
(US). Committee on Care, Use of Laboratory Animals, and National
Institutes of Health (US)Division of Research Resources: Guide for
the care and use of laboratory animals. 8th. National Academies
Press; Washington, DC: 2011
|
|
25
|
Kim WK, Chung MK, Kang NE, K0im MH and
Park OJ: Effect of resistant starch from corn or rice on glucose
control, colonic events and blood lipid concentrations in
streptozotocin-induced diabetic rats. J Nutr Biochem. 14:166–172.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Toden S, Bird AR, Topping DL and Conlon
MA: Resistant starch prevents colonic DNA damage induced by high
dietary cooked red meat or casein in rats. Cancer Biol Ther.
5:267–272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan HB, Gong ZB, Meng SH and He G:
Hypoglycemic and hypolipidemic effects of a triterpenoid-rich
extract from Euryale shell on streptozotocin-induced
diabetic mice. Pharmazie. 68:227–231. 2013.PubMed/NCBI
|
|
28
|
Zhao GH, Kan JQ, Li HJ and Chen Z: The
research progress of resistant starch in food. Liang Shi Yu You
Zhi. 14:37–40. 1999.(In Chinese).
|
|
29
|
Ma HB and Jia L: Progress in the stady of
resisaant starch. Di Si Jun Yi Da Xue Ji Lin Jun Yi Xue Yuan Xue
Bao. 24:174–176. 2002.(In Chinese).
|
|
30
|
Xu YJ, Fang RJ and Dai QZ: Physiological
role of short-chain fatty acids in nutrition. Si Liao Yan Jiu.
8:26–28. 2007.(In Chinese).
|
|
31
|
Gaede P, Vedel P, Lavsen N, Jensen GV,
Parving HH and Pedersen O: Multifactorial intervention and
cardiovascular disease in patients with type 2 diabetes. New Engl J
Med. 348:383–393. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bird AR, Brown IL and Topping DL:
Starches, resistant starches, the gut microflora and human health.
Curr Issues Intest Microbiol. 1:25–37. 2000.PubMed/NCBI
|
|
33
|
Luebeck EG and Moolgavkar SH: Multistage
carcinogenesis and the incidence of colorectal cancer. Proc Natl
Acad Sci USA. 99:15095–15100. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Archer MC, Bruce WR, Chan CC, Corpet DE,
Medline A, Roncicci L, Stamp D and Zhang XM: Aberrant crypt foci
and microadenoma as markers for colon cancer. Environ Health
Perspect. 98:195–197. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Muto T, Bussey HJ and Morson BC: The
evolution of cancer of the colon and rectum. Cancer. 36:2251–2270.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fearon ER and Vogelstein B: Genetic model
for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ and
Kang GH: Aberrant CpG island hypermethylation along multistep
hepatocarcinogenesis. Am J Pathol. 163:1371–1378. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Watson AJ, Merritt AJ, Jones LS, Askew JN,
Anderson E, Becciolini A, Balzi M, Potten CS and Hickman JA:
Evidence for reciprocity of bcl-2 and p53 expression in human
colorectal adenomas and carcinomas. Br J Cancer. 73:889–895. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin XY, Oltval ZN and Korsmeyer SJ: BH1
and BH2 domains of bcl-2 are required for inhibition of apoptosis
and heterodimerization with bax. Nature. 369:321–323. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhan Y: Butyric acid and tumor. Int J
Cancer. 30:350–353. 2003.
|
